<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Bezafibrate (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Bezafibrate (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Bezafibrate (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText"><div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
(For additional information <a class="drug drug_patient" data-topicid="11152" href="/d/html/11152.html" rel="external">see "Bezafibrate (United States: Not available): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="list canbnlist drugH1Div drugBrandNames" id="F52866076"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Bezalip SR;</li>
<li>JAMP-Bezafibrate SR</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F141181"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antilipemic Agent, Fibric Acid</li></ul></div>
<div class="block doa drugH1Div" id="F141145"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8cc49974-7a0b-4324-b3f2-23e5eeae1352">Hyperlipidemia, mixed</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperlipidemia, mixed:</b>
<b>Oral:</b> Sustained release: 400 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d5fe11c5-5429-4488-93aa-98e687a47477">Hypertriglyceridemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Hypertriglyceridemia (alternative agent) (adjunctive agent):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients requiring fibrate therapy, fenofibrate is generally preferred. All patients should receive general measures (ie, address modifiable causes, manage atherosclerotic cardiovascular disease [ASCVD] risk, implement lifestyle modification [eg, dietary changes, reduction of alcohol consumption]) and optimal low-density lipoprotein lowering therapy for 4 to 12 weeks before considering triglyceride lowering therapy. For patients whose triglycerides remain ≥500 mg/dL and who do not warrant icosapent ethyl for additional ASCVD risk reduction, either a fibrate or any prescription strength omega-3 fatty acid (including icosapent ethyl) is reasonable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34332805']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34332805'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Sustained release: 400 mg once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990027"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">CrCl ≥60 mL/minute: No dosage adjustment required</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">CrCl &lt;60 mL/minute <b>or</b> S<sub>cr</sub> &gt;1.5 mg/dL [&gt;135 micromol/L]: Use is contraindicated</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Dialysis: Use is contraindicated.</p></div>
<div class="block doha drugH1Div" id="F50987311"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Use is contraindicated.</p></div>
<div class="block doe drugH1Div" id="F2649926"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Patients ≤70 years of age: Refer to adult dosing.</p>
<p style="text-indent:-2em;margin-left:2em;">Patients &gt;70 years of age: Avoid use in patients &gt;70 years of age due to declining renal function and the likelihood of CrCl &lt;60 mL/minute in this population.</p></div>
<div class="block dop drugH1Div" id="F12617470"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f71eb8fe-d05e-4ef8-91ed-8e7a986cef46">Dyslipidemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dyslipidemia:</b> Children and Adolescents: Oral: 10 to 20 mg/kg/day (maximum: 400 mg daily). <b>Note:</b> Limited experience available; use caution. Based on child’s weight, dosing may not be possible as the manufacturer recommends administering the sustained release tablet whole.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block adr drugH1Div" id="F141108"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions are for immediate release formulation.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase in blood specimen</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Eczema (1%), pruritus (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Decreased appetite, diarrhea, dyspepsia (3%), flatulence (5%), gastritis (6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Anemia (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Hypersensitivity reaction (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (2%), headache, insomnia (1%), migraine (1%), pain (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchitis, pharyngitis</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia, erythema multiforme, skin photosensitivity, skin rash, toxic epidermal necrolysis, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distention, abdominal pain, cholelithiasis, cholestasis, constipation, nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased white blood cell count, immune thrombocytopenia, pancytopenia, thrombocytopenia</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Abnormal hepatic function tests (including decreased serum alkaline phosphatase, increased serum alkaline phosphatase, and increased serum transaminases), decreased gamma-glutamyl transferase, increased gamma-glutamyl transferase</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Depression, myasthenia, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Muscle cramps, myalgia, myositis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury, increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Interstitial pulmonary disease</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Purpuric rash (pigmented purpuric dermatosis) (Yung 2005), Stevens-Johnson syndrome (Sawamura 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Pancreatitis (Gang 1999)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (Frendo 2007), angioedema (Frendo 2007)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Peripheral neuropathy (Ellis 1994)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Rhabdomyolysis (Panuccio 1996)</p></div>
<div class="block coi drugH1Div" id="F141123"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to bezafibrate, fibrates, or any component of the formulation; photoallergic or phototoxic reactions to fibrates; hepatic impairment; primary biliary cirrhosis; renal impairment (serum creatinine &gt;1.5 mg/dL [&gt;135 micromol/L], CrCl &lt;60 mL/minute, or patients undergoing dialysis); pre-existing gallbladder disease; concomitant use with HMG CoA reductase inhibitors in patients predisposed to myopathy (eg, preexisting renal impairment, hormonal or electrolyte imbalance, severe infection, trauma, surgery); pregnancy or breast-feeding; not indicated for the treatment of type I hyperlipoproteinemia</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F141106"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Mild decreases in WBCs, platelets, and hemoglobin may occur following initiation of therapy; levels tend to stabilize with prolonged therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: Has been shown to be hepatotoxic; discontinue therapy if significant response is not obtained in 3 months. Use with caution in patients with history of jaundice or hepatic disorder. Abnormal liver function tests have been observed; discontinue therapy if abnormalities persist (reversible when discontinued). May increase risk for cholelithiasis; discontinue therapy in patients diagnosed with cholelithiasis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Myopathy/rhabdomyolysis: Has been associated with rare myositis or rhabdomyolysis (usually with renal impairment); monitor closely. Instruct patients to report unexplained muscle pain, tenderness, weakness, or brown urine. Evaluate creatine phosphokinase (CPK) levels with signs/symptoms of myotoxicity; discontinue therapy with marked elevation of CPK (10 x ULN) or diagnosis of myopathy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Due to the likelihood of renal impairment (CrCl &lt;60 mL/minute) in patients &gt;70 years of age, use is not recommended in this patient population.</p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Limited experience is available in children; therefore, caution should be used when treating children. Accurate dosing may not be achievable as sustained release tablet should be administered whole and not cut.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hyperlipidemia: Secondary causes of hyperlipidemia should be ruled out prior to therapy.</p></div>
<div class="block prod-avail drugH1Div" id="F11217333"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Not available in the US</p></div>
<div class="block geq drugH1Div" id="F53040713"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block dinfoc drugH1Div" id="F52866077"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Bezalip SR: 400 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 400 mg</p></div>
<div class="block adm drugH1Div" id="F141120"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Do not crush or chew tablet; should be swallowed whole with sufficient fluid. Administer in morning or evening with or after meals.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Cannot be cut or crushed. Switch to fenofibrate tablet.</p></div>
<div class="block admp drugH1Div" id="F52612307"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Sustained release: Do not crush or chew; tablet should be swallowed whole with sufficient fluid. Take in morning or evening with or after meals. Take a missed dose as soon as remembered unless it is almost time for the next dose, then skip the missed dose and continue your regular dosing schedule. Do not take 2 doses at the same time.</p></div>
<div class="block use drugH1Div" id="F141119"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Not approved in the United States.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hyperlipidemia, mixed or hypertriglyceridemia:</b> Adjunct to diet and other therapeutic measures for treatment of type IIa and IIb mixed hyperlipidemia, to regulate lipid and apoprotein levels (reduce serum TG, LDL-cholesterol, and apolipoprotein B, increase HDL-cholesterol and apolipoprotein A); treatment of adult patients with high to very high triglyceride levels (Fredrickson classification type IV and V hyperlipidemias) who are at high risk of sequelae and complications from their dyslipidemia.</p></div>
<div class="block cyt drugH1Div" id="F141177"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F141110"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acipimox: May enhance the myopathic (rhabdomyolysis) effect of Fibric Acid Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Fibric Acid Derivatives. Management: Separate doses by at least 2 hours to minimize this interaction; fenofibric acid labeling recommends administration one hour prior to or 4-6 hours after a bile acid sequestrant.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ciprofibrate: May enhance the adverse/toxic effect of Fibric Acid Derivatives.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colchicine: Fibric Acid Derivatives may enhance the myopathic (rhabdomyolysis) effect of Colchicine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): May enhance the nephrotoxic effect of Fibric Acid Derivatives. Fibric Acid Derivatives may decrease the serum concentration of CycloSPORINE (Systemic). Management: Careful consideration of the risks and benefits should be undertaken prior to use of this combination; extra monitoring of renal function and cyclosporine concentrations will likely be required.  Adjustment of cyclosporine dose may be necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ezetimibe: Fibric Acid Derivatives may enhance the adverse/toxic effect of Ezetimibe. Specifically, the risk of myopathy and cholelithiasis may be increased. Fibric Acid Derivatives may increase the serum concentration of Ezetimibe. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">HMG-CoA Reductase Inhibitors (Statins): Bezafibrate may enhance the myopathic (rhabdomyolysis) effect of HMG-CoA Reductase Inhibitors (Statins). Bezafibrate may increase the serum concentration of HMG-CoA Reductase Inhibitors (Statins). More specifically, bezafibrate may increase the serum concentration of fluvastatin  Management: Avoid use of bezafibrate and HMG-CoA reductase inhibitors (statins) unless strictly indicated due to the increased of muscle toxicity (including rhabdomyolysis). In patients who may be predisposed to myopathy, concomitant use is contraindicated.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mizoribine: May enhance the adverse/toxic effect of Bezafibrate. Specifically, the risk for muscle toxicities may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the adverse/toxic effect of Bezafibrate.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Raltegravir: May enhance the myopathic (rhabdomyolysis) effect of Fibric Acid Derivatives.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonylureas: Fibric Acid Derivatives may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Fibric Acid Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Consider reducing the oral anticoagulant dose by 25% to 33% when initiating a fibric acid derivative. Monitor for toxic or reduced anticoagulant effects if a fibric acid derivative is initiated/dose increased, or discontinued/dose decreased, respectively.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49095586"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Effective contraception is recommended when used in females of reproductive potential. Women planning pregnancy should discontinue bezafibrate several months before conception.</p></div>
<div class="block pri drugH1Div" id="F141126"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in pregnant women. Therapy should be discontinued in women who become pregnant during therapy.</p></div>
<div class="block brc drugH1Div" id="F141127"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if bezafibrate is excreted in breast milk. Use in breastfeeding women is contraindicated.</p></div>
<div class="block dic drugH1Div" id="F141128"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Before initiation of therapy, patients should be placed on a standard lipid-lowering diet for 6 weeks and the diet should be continued during drug therapy.</p></div>
<div class="block mop drugH1Div" id="F141115"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Periodic evaluation of serum lipids, cholesterol, and triglycerides (especially in the first few months of therapy). LFTs after 3-6 months; then at least annually. CBC (periodically during the first 12 months). Fasting glucose, creatinine, and CPK periodically.</p></div>
<div class="block pha drugH1Div" id="F141105"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Mechanism not definitely established; may increase VLDL catabolism by increasing lipoprotein and hepatic triglyceride lipase activities; attenuation of triglyceride biosynthesis by inhibition of acetyl-CoA carboxylase; decreased cholesterol biosynthesis by inhibition of 3-hydroxy-3-methyglutaryl-coenzyme A reductase</p></div>
<div class="block phk drugH1Div" id="F141122"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Distribution: ~17 L </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: 94% to 96% </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 1-2 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: 3-4 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (95%); feces (3%)</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F141129"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Lipitrol</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Bezacur | Bezalip | Elpi lip</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Bezafibrat | Bezafibrate 1a pharma gmbh | Bezafibrate arcana | Bezafibrate genericon pharma | Bezalip | Bezastad</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Cedur | Eulitop</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Bezafibrato | Cedur | Cedur retard</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Cedur | Cedur retard</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Bezacur | Nimus | Oralipin</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A bei ta | Bezafibrat Stada | Bezafibrate stada | Bezalip | Yi zhi te</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Bezafibrato | Bezalip</span>;</li>
<li>
<span class="countryCode">(CY)</span> <span class="country">Cyprus</span><span class="countrySeparator">: </span><span class="drugName">Lacromid</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Regadrin b</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Azufibrat | Befibrat | Befizal | Beza | Beza AbZ | Beza retard | Beza-lande | Beza-puren | Bezabeta | Bezacur | Bezadoc | Bezafibrat | Bezafibrat AL | Bezafibrat CT | Bezafibrat Dura | Bezafibrat Heumann | Bezafibrat hexal | Bezafibrat Stada | Bezafibrat-ratiopharm | Bezagamma | Bezamerck | Bezapham | Cedur | Durabezur | Lipox</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Bezalip</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Benzafibrato | Bezafibrato | Bezalip | Nimus</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Bezafibrat AL</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Epibeza</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Difaterol | Eulitop | Reducterol</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Bezafibrat generic | Bezalip</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Befizal | Befizal lp | Bezafibrate Dci</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bezafibrate kent | Bezafibrate sandoz | Bezagen | Bezalip | Fibrazate | Fibrazate xl | Liparol | Zimbacol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Getup | Verbital</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Zafibral</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Bezafibrat-q | Bezalip | Bezamidin</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Decrilip</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bezalip</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Norlip</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Beza-xl | Bezalip | Globez</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Bezafibrato EG | Bezalip | Hadiel</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Zafibral</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Anibesol | Befarlart | Beriatol | Besastar | Betlol | Bezalex | Bezalip | Bezasafe | Bezatate sr fuso | Bezatate sr sawai | Bezaterio | Bezatol | Bunatol | Busyarlu | Kenperate | Midenal l | Midenal l choseido | Midenal l merck hoei | Midenal l nagase | Midenal l teisan | Midenal l towa | Modobil | Natoris | Vesturit l</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bezacolin | Bezafirol | Bezalip | Bezalip sr | Bezasterol | Demia</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Bezalip</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Bezafibrat AL | Bezalip | Bezamidin</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Bezacur | Bezafibrat hexal | Cedur | Eulitop</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Bezafibrat | Bezalip | Bezamidin</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Befitec | Bexalcor | Bezafibrato | Bezafibrato gi bru | Bezafibrato gi ken | Bezafibrato gi ser | Bezafibrato novag | Bezafibrato Silanes | Bezafibrato teva | Bezafisal | Bezalip | Bezalip retard | Bifaren | Bionolip | Brufiza | Colser | Ergol | Fazebit | Fibroxol | Neptalip | Nibezvag | Nivetril | Nivezvag | Redalip | Safital | Saprame | Solibay | Tridegort | Triglesan | Wayfrato | Zaf</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Bezamidin</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Bezalip</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Bezalip retard</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Fibalip</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Clofibral</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Bezastad</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Lipocor</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Bezamidin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Bezafibrato | Bezalip</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Becolestol retard | Bezafibrato Heisecke | Bezafibrato Svant Pharma | Clofibral | Dombrozil 400 a.s. | Oralipin | Sebel</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Lipitrol (Julphar)</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Bezafibrat slavia | Bezalip | Bezamidin | Regadrin b | Verbital</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cholestenorm</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Bezalip</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Bezalip</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Bezafibrat Stada | Bezalip | Zafibral</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Regadrin b</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Bezamil | Evicta | Lipolip | Polyzalip | Raset</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Antilip | Befat | Betapid | Bezafite | Bezalip | Bezalite | Bezilon | Bezin | Bonalip | Cegelin | Chaze | Chinsa | Chinsalo | Cloestin | Colibrate | Eulip | Fevilon | Fizate | Ligisin | Susheu</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Becolestol | Bezalip</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Bezalip | Detrex</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Zafular</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Bezachole | Bezalip | Dyna Bezafibrate | Rolab-bezafibrate</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-Bezalip.1">
<a name="Bezalip.1"></a>Bezalip SR (bezafibrate) [product monograph]. Mississauga, Ontario, Canada: Aralez Pharmaceuticals Canada Inc; October 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7950666">
<a name="7950666"></a>Ellis CJ, Wallis WE, Caruana M. Peripheral neuropathy with bezafibrate. <i>BMJ</i>. 1994;309(6959):929. doi:10.1136/bmj.309.6959.929b<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/7950666/pubmed" id="7950666" target="_blank">7950666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9359536">
<a name="9359536"></a>Ericsson CG, Nilsson J, Grip L, et al. Effect of Bezafibrate Treatment Over Five Years on Coronary Plaques Causing 20% to 50% Diameter Narrowing (The Bezafibrate Coronary Atherosclerosis Intervention Trial [BECAIT]). <i>Am J Cardiol</i>. 1997;80(9):1125-1129.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/9359536/pubmed" id="9359536" target="_blank">9359536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11368702">
<a name="11368702"></a>Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). <i>JAMA</i>. 2001;285(19):2486-2497.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/11368702/pubmed" id="11368702" target="_blank">11368702</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17610533">
<a name="17610533"></a>Frendo M, Theuma R, Fava S. Delayed bezafibrate-induced angio-oedema in a 68-year-old man. <i>Br J Clin Pharmacol</i>. 2007;64(4):560-561. doi:10.1111/j.1365-2125.2007.02915.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/17610533/pubmed" id="17610533" target="_blank">17610533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10606331">
<a name="10606331"></a>Gang N, Langevitz P, Livneh A. Relapsing acute pancreatitis induced by re-exposure to the cholesterol lowering agent bezafibrate. <i>Am J Gastroenterol</i>. 1999;94(12):3626-3628. doi:10.1111/j.1572-0241.1999.01621.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/10606331/pubmed" id="10606331" target="_blank">10606331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19812802">
<a name="19812802"></a>Genest J, McPherson R, Frohlich J, et al. 2009 Canadian Cardiovascular Society/Canadian Guidelines for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease in the Adult – 2009 Recommendations. <i>Can J Cardiol</i>. 2009;25(10):567-579.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/19812802/pubmed" id="19812802" target="_blank">19812802</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16971976">
<a name="16971976"></a>McPherson R, Frohlich J, Fodor G, et al. Canadian Cardiovascular Society Position Statement--Recommendations for the Diagnosis and Treatment of Dyslipidemia and Prevention of Cardiovascular Disease. [published correction appears in <i>Can J Cardiol</i>. 2006;22(12):1077]. <i>Can J Cardiol</i>. 2006;22(11):913-927.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/16971976/pubmed" id="16971976" target="_blank">16971976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8856294">
<a name="8856294"></a>Panuccio V, Enia G, Parlongo S, Cutrupi S, Zoccali C. Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient. <i>Nephron</i>. 1996;73(4):736. doi:10.1159/000189184<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/8856294/pubmed" id="8856294" target="_blank">8856294</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11243650">
<a name="11243650"></a>Sawamura D, Umeki K. Stevens-Johnson syndrome associated with bezafibrate. <i>Acta Derm Venereol</i>. 2000;80(6):457. doi:10.1080/000155500300080457<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/11243650/pubmed" id="11243650" target="_blank">11243650</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10880410">
<a name="10880410"></a>Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease: The Bezafibrate Infarction Prevention (BIP) Study. The BIP Study Group. <i>Circulation</i>. 2000;102(1):21-27<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/10880410/pubmed" id="10880410" target="_blank">10880410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34332805">
<a name="34332805"></a>Virani SS, Morris PB, Agarwala A, et al. 2021 ACC expert consensus decision pathway on the management of ASCVD risk reduction in patients with persistent hypertriglyceridemia: a report of the American College of Cardiology solution set oversight committee. <i>J Am Coll Cardiol</i>. 2021;78(9):960-993. doi:10.1016/j.jacc.2021.06.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/34332805/pubmed" id="34332805" target="_blank">34332805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15965444">
<a name="15965444"></a>Yung A, Goulden V. Pigmented purpuric dermatosis (capillaritis) induced by bezafibrate. <i>J Am Acad Dermatol</i>. 2005;53(1):168-169. doi:10.1016/j.jaad.2005.04.072<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/bezafibrate-united-states-not-available-drug-information/abstract-text/15965444/pubmed" id="15965444" target="_blank">15965444</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 8696 Version 146.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
